As a large claims underwriter, insurer and reinsurer, BCS has seen our fair share of high-cost claims. Our industry is grappling to absorb rising catastrophic claims, as additional cost drivers like inflation and new pharmaceuticals continue to put pressure on bottom lines. A recent PwC Behind the Numbers 2026 report indicates that “medical cost trend is once again hovering at rates reminiscent of 15 years ago, projected to be at 8.5% for 2026.”
Like many carriers, we’ve seen high-cost claims grow at an alarming rate. In 2024, the BCS Large Claims Solutions business paid 21 claims in excess of $2M (ground-up allowed charges) across a $329M portfolio of stop loss and reinsurance. This includes 11 gene therapy claims, totaling over $30M. The most notable of those claimants are summarized below.
Fill out the form to access the most notable claims of 2024.
"*" indicates required fields
